Description: Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.
Home Page: www.immuron.com.au
IMC Technical Analysis
62 Lygon Street
Carlton,
VIC
3053
Australia
Phone:
61 3 9824 5254
Officers
| Name | Title |
|---|---|
| Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA | Chief Exec. Officer |
| Dr. Jerry Kanellos Ph.D. | Chief Operating Officer |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | CFO & Company Sec. |
| Mr. David Lyon | Head of Marketing |
| Dr. Dan Ruben Peres | Chief Medical Officer |
| Mr. Flavio Palumbo | Chief Commercial Officer |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7863 |
| Price-to-Sales TTM: | 23.2206 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 5 |